A Special View of What Was Almost Forgotten: p38δ MAPK
Abstract
:Simple Summary
Abstract
1. Introduction
2. p38δ MAPK in Cancer-Suppressor or Promoter?
3. Searching Specific p38δ MAPK Inhibitors
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Plotnikov, A.; Zehorai, E.; Procaccia, S.; Seger, R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta Mol. Cell Res. 2011, 1813, 1619–1633. [Google Scholar] [CrossRef] [Green Version]
- Kim, E.K.; Choi, E.J. Compromised MAPK signaling in human diseases: An update. Arch. Toxicol. 2015, 89, 867–882. [Google Scholar] [CrossRef]
- Kim, E.K.; Choi, E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2010, 1802, 396–405. [Google Scholar] [CrossRef] [Green Version]
- Cuenda, A.; Rousseau, S. p38 MAP-Kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta Mol. Cell Res. 2007, 1773, 1358–1375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cuadrado, A.; Nebreda, A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429, 403–417. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Remy, G.; Risco, A.M.; Iñesta-Vaquera, F.A.; González-Terán, B.; Sabio, G.; Davis, R.J.; Cuenda, A. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell. Signal. 2010, 22, 660–667. [Google Scholar] [CrossRef] [PubMed]
- Brancho, D.; Tanaka, N.; Jaeschke, A.; Ventura, J.J.; Kelkar, N.; Tanaka, Y.; Kyuuma, M.; Takeshita, T.; Flavell, R.A.; Davis, R.J. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003, 17, 1969–1978. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yurtsever, Z.; Scheaffer, S.M.; Romero, A.G.; Holtzman, M.J.; Brett, T.J. The crystal structure of phosphorylated MAPK13 reveals common structural features and differences in p38 MAPK family activation. Acta Cryst. Sect. D Biol. Crystallogr. 2015, 71, 790–799. [Google Scholar] [CrossRef] [PubMed]
- Del Barco Barrantes, I.; Coya, J.M.; Maina, F.; Arthurd, J.S.C.; Nebreda, A.R. Genetic analysis of specific and redundant roles for p38α and p38β MAPKs during mouse development. Proc. Natl. Acad. Sci. USA 2011, 108, 12764–12769. [Google Scholar] [CrossRef] [Green Version]
- Goedert, M.; Cuenda, A.; Craxton, M.; Jakes, R.; Cohen, P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J. 1997, 16, 3563–3571. [Google Scholar] [CrossRef] [Green Version]
- Goedert, M.; Hasegawa, M.; Jakes, R.; Lawler, S.; Cuenda, A.; Cohen, P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett. 1997, 409, 57–62. [Google Scholar] [CrossRef]
- Koul, H.K.; Pal, M.; Koul, S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer 2013, 4, 342–359. [Google Scholar] [CrossRef]
- Martínez-Limón, A.; Joaquin, M.; Caballero, M.; Posas, F.; de Nadal, E. The p38 pathway: From biology to cancer therapy. Int. J. Mol. Sci. 2020, 21, 1913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, R.H.; Porras, A.; Alonso, G.; Jones, M.; Vintersten, K.; Panelli, S.; Valladares, A.; Perez, L.; Klein, R.; Nebreda, A.R. Essential role of p38α MAP kinase in placental but not embryonic cardiovascular development. Mol. Cell 2000, 6, 109–116. [Google Scholar] [CrossRef]
- Mudgett, J.S.; Ding, J.; Guh-Siesel, L.; Chartrain, N.A.; Yang, L.; Gopal, S.; Shen, M.M. Essential role for p38α mitogen-activated protein kinase in placental angiogenesis. Proc. Natl. Acad. Sci. USA 2000, 97, 10454–10459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sabio, G.; Arthur, J.S.C.; Kuma, Y.; Peggie, M.; Carr, J.; Murray-Tait, V.; Centeno, F.; Goedert, M.; Morrice, N.A.; Cuenda, A. p38γ regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J. 2005, 24, 1134–1145. [Google Scholar] [CrossRef]
- Sumara, G.; Formentini, I.; Collins, S.; Sumara, I.; Windak, R.; Bodenmiller, B.; Ramracheya, R.; Caille, D.; Jiang, H.; Platt, K.A.; et al. Regulation of PKD by the MAPK p38δ in Insulin Secretion and Glucose Homeostasis. Cell 2009, 136, 235–248. [Google Scholar] [CrossRef] [PubMed]
- Risco, A.; del Fresno, C.; Mambol, A.; Alsina-Beauchamp, D.; MacKenzie, K.F.; Yang, H.-T.; Barber, D.F.; Morcelle, C.; Arthur, J.S.C.; Ley, S.C.; et al. p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc. Natl. Acad. Sci. USA 2012, 109, 11200–11205. [Google Scholar] [CrossRef] [Green Version]
- Alevy, Y.G.; Patel, A.C.; Romero, A.G.; Patel, D.A.; Tucker, J.; Roswit, W.T.; Miller, C.A.; Heier, R.F.; Byers, D.E.; Brett, T.J.; et al. IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. J. Clin. Investig. 2012, 122, 4555–4568. [Google Scholar] [CrossRef] [Green Version]
- Cuenda, A.; Sanz-Ezquerro, J.J. p38γ and p38δ: From Spectators to Key Physiological Players. Trends Biochem. Sci. 2017, 42, 431–442. [Google Scholar] [CrossRef]
- Wang, X.S.; Diener, K.; Manthey, C.L.; Wang, S.-W.; Rosenzweig, B.; Bray, J.; Delaney, J.; Cole, C.N.; Chan-Hui, P.-Y.; Mantlo, N.; et al. Molecular Cloning and Characterization of a Novel p38 Mitogen-activated Protein Kinase. J. Biol. Chem. 1997, 272, 23668–23674. [Google Scholar] [CrossRef] [Green Version]
- Escós, A.; Risco, A.; Alsina-Beauchamp, D.; Cuenda, A. p38γ and p38δ Mitogen Activated Protein Kinases (MAPKs), New Stars in the MAPK Galaxy. Front. Cell Dev. Biol. 2016, 4, 31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feijoo, C.; Campbell, D.G.; Jakes, R.; Goedert, M.; Cuenda, A. Evidence that phosphorylation of the microtubule-associated protein Tau by SAPK4/p38δ at Thr50 promotes microtubule assembly. J. Cell Sci. 2005, 118, 397–408. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Johansen, C.; Kragballe, K.; Westergaard, M.; Henningsen, J.; Kristiansen, K.; Iversen, L. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br. J. Dermatol. 2005, 152, 37–42. [Google Scholar] [CrossRef]
- Criado, G.; Risco, A.; Alsina-Beauchamp, D.; Pérez-Lorenzo, M.J.; Escõs, A.; Cuenda, A. Alternative p38 MAPKs are essential for collagen-induced arthritis. Arthritis Rheumatol. 2014, 66, 1208–1217. [Google Scholar] [CrossRef]
- Tan, F.L.S.; Ooi, A.; Huang, D.; Wong, J.C.; Qian, C.N.; Chao, C.; Ooi, L.; Tan, Y.M.; Chung, A.; Cheow, P.C.; et al. p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int. J. Cancer 2010, 126, 2353–2361. [Google Scholar] [CrossRef]
- Wada, M.; Canals, D.; Adada, M.; Arthur, J.S.; Hannun, Y.A.; Salama, M.F.; Coant, N.; Obeid, L.M.; Shroyer, K.R.; Kitatani, K.; et al. P38 delta MAPK promotes breast cancer progression and lung metastasis by enhancing cell proliferation and cell detachment. Oncogene 2017, 36, 6649–6657. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sahu, V.; Nigam, L.; Agnihotri, V.; Gupta, A.; Shekhar, S.; Subbarao, N.; Bhaskar, S.; Dey, S. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative serum level evaluation and design of novel peptide inhibitor targeting the same. Cancer Res. Treat. 2019, 51, 313–325. [Google Scholar] [CrossRef] [PubMed]
- Kiss, A.; Koppel, A.C.; Murphy, E.; Sall, M.; Barlas, M.; Kissling, G.; Efimova, T. Cell type-specific p38δ targeting reveals a context-, stage-, and sex-dependent regulation of skin carcinogenesis. Int. J. Mol. Sci. 2019, 20, 1532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Junttila, M.R.; Ala-Aho, R.; Jokilehto, T.; Peltonen, J.; Kallajoki, M.; Grenman, R.; Jaakkola, P.; Westermarck, J.; Kähäri, V.M. p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007, 26, 5267–5279. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cerezo-guisado, M.I.; del Reino, P.; Remy, G.; Kuma, Y.; Arthur, J.S.C.; Gallego-Ortega, D.; Cuenda, A. Evidence of p38γ and p38δ involvement in cell transformation processes. Carcinogenesis 2011, 32, 1093–1099. [Google Scholar] [CrossRef]
- O’Callaghan, C.; Fanning, L.J.; Houston, A.; Barry, O.P. Loss of p38δ expression promotes oesophageal squamous cell carcinoma proliferation, migration and anchorage-independent growth. Int. J. Oncol. 2013, 43, 405–415. [Google Scholar] [CrossRef] [Green Version]
- Del Reino, P.; Alsina-Beauchamp, D.; Escós, A.; Cerezo-Guisado, M.I.; Risco, A.; Aparicio, N.; Zur, R.; Fernandez-Estévez, M.; Collantes, E.; Montans, J.; et al. Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38γ and p38δ, linking inflammation and cancer in colitis-associated colon cancer. Cancer Res. 2014, 74, 6150–6160. [Google Scholar] [CrossRef] [Green Version]
- Wu, P.; Nielsen, T.E.; Clausen, M.H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 2015, 36, 422–439. [Google Scholar] [CrossRef] [Green Version]
- Haller, V.; Nahidino, P.; Forster, M.; Laufer, S.A. An updated patent review of p38 MAP kinase inhibitors (2014–2019). Expert Opin. Ther. Pat. 2020, 30, 453–466. [Google Scholar] [CrossRef] [PubMed]
- Alonso, G.; Ambrosino, C.; Jones, M.; Nebreda, A.R. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength. J. Biol. Chem. 2000, 275, 40641–40648. [Google Scholar] [CrossRef] [Green Version]
- Risco, A.; Cuenda, A. New Insights into the p38 γ and p38 δ MAPK Pathways. J. Signal Transduct. 2012, 2012, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Q.; Zou, R.; Zhou, R.; Gong, C.; Wang, Z.; Cai, T.; Tan, C.; Fang, J. MiR-155 regulates glioma cells invasion and chemosensitivity by p38 isforms in vitro. J. Cell. Biochem. 2015, 116, 1213–1221. [Google Scholar] [CrossRef]
- Winer, A.; Adams, S.; Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol. Cancer Ther. 2018, 17, 1147–1155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Webb, A.H.; Gao, B.T.; Goldsmith, Z.K.; Irvine, A.S.; Saleh, N.; Lee, R.P.; Lendermon, J.B.; Bheemreddy, R.; Zhang, Q.; Brennan, R.C.; et al. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC Cancer 2017, 17. [Google Scholar] [CrossRef]
- O’Callaghan, C.; Fanning, L.J.; Barry, O.P. p38δ MAPK phenotype: An indicator of chemotherapeutic response in oesophageal squamous cell carcinoma. Anticancer Drugs 2015, 26, 46–55. [Google Scholar] [CrossRef] [Green Version]
- O’Callaghan, C.; Fanning, L.J.; Barry, O.P. Hypermethylation of MAPK13 promoter in oesophageal squamous cell carcinoma is associated with loss of p38δ MAPK expression. Cancers 2015, 7, 2124–2133. [Google Scholar] [CrossRef] [Green Version]
- Gao, L.; Smit, M.A.; van den Oord, J.J.; Goeman, J.J.; Verdegaal, E.M.E.; van der Burg, S.H.; Stas, M.; Beck, S.; Gruis, N.A.; Tensen, C.P.; et al. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma. Pigment Cell Melanoma Res. 2013, 26, 542–554. [Google Scholar] [CrossRef]
- Schindler, E.M.; Hindes, A.; Gribben, E.L.; Burns, C.J.; Yin, Y.; Lin, M.H.; Owen, R.J.; Longmore, G.D.; Kissling, G.E.; Arthur, J.S.C.; et al. p38δ mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res. 2009, 69, 4648–4655. [Google Scholar] [CrossRef] [Green Version]
- Zur, R.; Garcia-Ibanez, L.; Nunez-Buiza, A.; Aparicio, N.; Liappas, G.; Escós, A.; Risco, A.; Page, A.; Saiz-Ladera, C.; Alsina-Beauchamp, D.; et al. Combined deletion of p38γ and p38δ reduces skin inflammation and protects from carcinogenesis. Oncotarget 2015, 6, 12920–12935. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhong, J.; Lardinois, D.; Szilard, J.; Tamm, M.; Roth, M. Rat mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α. Lung Cancer 2011, 73, 166–170. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.X.; Craig, A.J.; Duffy, M.E.; Villacorta-Martin, C.; Miguela, V.; de Galarreta, M.R.; Scopton, A.P.; Silber, L.; Maldonado, A.Y.; Rialdi, A.; et al. Phenotype-based screens with conformation-specific inhibitors reveal p38 gamma and delta as targets for HCC polypharmacology. Mol. Cancer Ther. 2019, 18, 1506–1519. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, D.J.; Chan, K.S.; Sano, S.; DiGiovanni, J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol. Carcinog. 2007, 46, 725–731. [Google Scholar] [CrossRef]
- Park, C.Y.; Tseng, D.; Weissman, I.L. Cancer stem cell-directed therapies: Recent data from the laboratory and clinic. Mol. Ther. 2009, 17, 219–230. [Google Scholar] [CrossRef] [PubMed]
- Barbato, L.; Bocchetti, M.; Di Biase, A.; Regad, T. Cancer Stem Cells and Targeting Strategies. Cells 2019, 8, 926. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yasuda, K.; Hirohashi, Y.; Kuroda, T.; Takaya, A.; Kubo, T.; Kanaseki, T.; Tsukahara, T.; Hasegawa, T.; Saito, T.; Sato, N.; et al. MAPK13 is preferentially expressed in gynecological cancer stem cells and has a role in the tumor-initiation. Biochem. Biophys. Res. Commun. 2016, 472, 643–647. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, Inflammation, and Cancer. Cell 2010, 140, 883–899. [Google Scholar] [CrossRef] [Green Version]
- Ittner, A.; Block, H.; Reichel, C.A.; Varjosalo, M.; Gehart, H.; Sumara, G.; Gstaiger, M.; Krombach, F.; Zarbock, A.; Ricci, R. Regulation of PTEN activity by p38δ-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J. Exp. Med. 2012, 209, 2229–2246. [Google Scholar] [CrossRef] [Green Version]
- Barrio, L.; Román-García, S.; Díaz-Mora, E.; Risco, A.; Jiménez-Saiz, R.; Carrasco, Y.R.; Cuenda, A. B Cell Development and T-Dependent Antibody Response Are Regulated by p38γ and p38δ. Front. Cell Dev. Biol. 2020, 8, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Kitatani, K.; Sheldon, K.; Anelli, V.; Jenkins, R.W.; Sun, Y.; Grabowski, G.A.; Obeid, L.M.; Hannun, Y.A. Acid β-Glucosidase 1 Counteracts p38δ-dependent Induction of Interleukin-6: Possible role for ceramide as an anti-inflammatory lipid. J. Biol. Chem. 2009, 284, 12979–12988. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, Y.; Zhou, B.P. Inflammation: A driving force speeds cancer metastasis. Cell Cycle 2009, 8, 3267–3273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crusz, S.M.; Balkwill, F.R. Inflammation and cancer: Advances and new agents. Nat. Rev. Clin. Oncol. 2015, 12, 584–596. [Google Scholar] [CrossRef] [PubMed]
- Holen, I.; Lefley, D.V.; Francis, S.E.; Rennicks, S.; Bradbury, S.; Coleman, R.E.; Ottewell, P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget 2016, 7, 75571–75584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [Green Version]
- Yamada, T.; Oshima, T.; Yoshihara, K.; Tamura, S.; Kanazawa, A.; Inagaki, D.; Yamamoto, N.; Sato, T.; Fujii, S.; Numata, K.; et al. Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res. 2010, 30, 2693–2699. [Google Scholar]
- Wang, J.; Ye, C.; Lu, D.; Chen, Y.; Jia, Y.; Ying, X.; Xiong, H.; Zhao, W.; Zhou, J.; Wang, L. Matrix metalloproteinase-1 expression in breast carcinoma: A marker for unfavorable prognosis. Oncotarget 2017, 8, 91379–91390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tian, R.; Li, X.; Gao, Y.; Li, Y.; Yang, P.; Wang, K. Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer. Int. J. Oncol. 2018, 52, 1198–1208. [Google Scholar] [CrossRef]
- Gonzalez-Avila, G.; Sommer, B.; Mendoza-Posada, D.A.; Ramos, C.; Garcia-Hernandez, A.A.; Falfan-Valencia, R. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit. Rev. Oncol. Hematol. 2019, 137, 57–83. [Google Scholar] [CrossRef] [PubMed]
- Shi, D.B.; Ma, R.R.; Zhang, H.; Hou, F.; Guo, X.Y.; Gao, P. GAGE7B promotes tumor metastasis and growth via activating the p38δ/pMAPKAPK2/pHSP27 pathway in gastric cancer. J. Exp. Clin. Cancer Res. 2019, 38, 124. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kato, K.; Ito, H.; Iwamoto, I.; Iida, K.; Inaguma, Y. Protein kinase inhibitors can suppress stress-induced dissociation of Hsp27. Cell Stress Chaperones 2001, 6, 16–20. [Google Scholar] [CrossRef] [Green Version]
- Nakashima, M.; Adachi, S.; Yasuda, I.; Yamauchi, T.; Kawaguchi, J.; Itani, M.; Yoshioka, T.; Matsushima-Nishiwaki, R.; Hirose, Y.; Kozawa, O.; et al. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Lett. 2011, 313, 218–225. [Google Scholar] [CrossRef]
- Lambert, A.W.; Pattabiraman, D.R.; Weinberg, R.A. Emerging Biological Principles of Metastasis. Cell 2017, 168, 670–691. [Google Scholar] [CrossRef] [Green Version]
- Lee, M.; Dominguez, C. MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein. Curr. Med. Chem. 2005, 12, 2979–2994. [Google Scholar] [CrossRef]
- Murphy, A.G.; Zheng, L. Small molecule drugs with immunomodulatory effects in cancer. Hum. Vaccines Immunother. 2015, 11, 2463–2468. [Google Scholar] [CrossRef] [Green Version]
- Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol. Res. 2020, 152, 104609. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Shen, B.; Lin, A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci. 2007, 28, 286–295. [Google Scholar] [CrossRef]
- Tong, M.; Seeliger, M.A. Targeting conformational plasticity of protein kinases. ACS Chem. Biol. 2015, 10, 190–200. [Google Scholar] [CrossRef] [PubMed]
- Kumar, G.S.; Clarkson, M.W.; Kunze, M.B.A.; Granata, D.; Joshua Wand, A.; Lindorff-Larsen, K.; Page, R.; Peti, W. Dynamic activation and regulation of the mitogen-activated protein kinase p38. Proc. Natl. Acad. Sci. USA 2018, 115, 4655–4660. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huse, M.; Kuriyan, J. The Conformational Plasticity of Protein Kinases. Cell 2002, 109, 275–282. [Google Scholar] [CrossRef] [Green Version]
- Filomia, F.; De Rienzo, F.; Menziani, M.C. Insights into MAPK p38α DFG flip mechanism by accelerated molecular dynamics. Bioorganic Med. Chem. 2010, 18, 6805–6812. [Google Scholar] [CrossRef]
- Ung, P.M.U.; Schlessinger, A. DFGmodel: Predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. ACS Chem. Biol. 2015, 10, 269–278. [Google Scholar] [CrossRef]
- Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the “gatekeeper door”: Exploiting the active kinase conformation. J. Med. Chem. 2010, 53, 2681–2694. [Google Scholar] [CrossRef]
- Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Grob, P.M.; Hickey, E.R.; Moss, N.; Pav, S.; et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9, 268–272. [Google Scholar] [CrossRef]
- Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9, 28–39. [Google Scholar] [CrossRef]
- Koeberle, S.C.; Romir, J.; Fischer, S.; Koeberle, A.; Schattel, V.; Albrecht, W.; Grütter, C.; Werz, O.; Rauh, D.; Stehle, T.; et al. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat. Chem. Biol. 2012, 8, 141–143. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Canagarajah, B.J.; Boehm, J.C.; Kassisà, S.; Cobb, M.H.; Young, P.R.; Abdel-Meguid, S.; Adams, J.L.; Goldsmith, E.J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117–1128. [Google Scholar] [CrossRef] [Green Version]
- Kufareva, I.; Abagyan, R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J. Med. Chem. 2009, 51, 7921–7932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wentsch, H.K.; Walter, N.M.; Bührmann, M.; Mayer-Wrangowski, S.; Rauh, D.; Zaman, G.J.R.; Willemsen-Seegers, N.; Buijsman, R.C.; Henning, M.; Dauch, D.; et al. Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine. Angew. Chem. Int. Ed. 2017, 56, 5363–5367. [Google Scholar] [CrossRef] [PubMed]
- Walter, N.M.; Wentsch, H.K.; Bührmann, M.; Bauer, S.M.; Döring, E.; Mayer-Wrangowski, S.; Sievers-Engler, A.; Willemsen-Seegers, N.; Zaman, G.; Buijsman, R.; et al. Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. J. Med. Chem. 2017, 60, 8027–8054. [Google Scholar] [CrossRef]
- Kondoh, Y.; Honda, K.; Hiranuma, S.; Hayashi, T.; Shimizu, T.; Watanabe, N.; Osada, H. Comparative chemical array screening for p38π/σ MAPK inhibitors using a single gatekeeper residue difference between p38α/β and p38π/σ. Sci. Rep. 2016, 6, 29881. [Google Scholar] [CrossRef] [Green Version]
- Eyers, P.A.; Craxton, M.; Morrice, N.; Cohen, P.; Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 1998, 5, 321–328. [Google Scholar] [CrossRef]
- Yurtsever, Z.; Patel, D.A.; Kober, D.L.; Su, A.; Miller, C.A.; Romero, A.G.; Holtzman, M.J.; Brett, T.J. First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. Biochim. Biophys. Acta Gen. Subj. 2016, 1860, 2335–2344. [Google Scholar] [CrossRef] [Green Version]
- Stramucci, L.; Bossi, G. Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer. J. Exp. Clin. Cancer Res. 2019, 38, 19–21. [Google Scholar] [CrossRef]
- Stramucci, L.; Pranteda, A.; Stravato, A.; Amoreo, C.A.; Pennetti, A.; Diodoro, M.G.; Bartolazzi, A.; Milella, M.; Bossi, G. MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer. Cell Death Dis. 2019, 10, 842. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Anton, D.B.; Ducati, R.G.; Timmers, L.F.S.M.; Laufer, S.; Goettert, M.I. A Special View of What Was Almost Forgotten: p38δ MAPK. Cancers 2021, 13, 2077. https://doi.org/10.3390/cancers13092077
Anton DB, Ducati RG, Timmers LFSM, Laufer S, Goettert MI. A Special View of What Was Almost Forgotten: p38δ MAPK. Cancers. 2021; 13(9):2077. https://doi.org/10.3390/cancers13092077
Chicago/Turabian StyleAnton, Débora Bublitz, Rodrigo Gay Ducati, Luís Fernando Saraiva Macedo Timmers, Stefan Laufer, and Márcia Inês Goettert. 2021. "A Special View of What Was Almost Forgotten: p38δ MAPK" Cancers 13, no. 9: 2077. https://doi.org/10.3390/cancers13092077